The role of real world data and real world evidence in health technology assessment
Open Access
- 9 October 2022
- journal article
- research article
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 15 (3) , 380-389
Abstract
Real world data (RWD) and real world evidence (RWE) is one of the most rapidly developing areas in the modern health care systems, which is caused by the development of technologies for both collecting and analyzing data, the emergence of new data sources and the formation of needs both by regulatory bodies, health technology assessment (HTA) agencies, and by the clinical and scientific communities. However, at the moment, there is no universal approach to RWD/E generation and application in the context of HTA. Over the past few years, the rate of including RWD/E in the HTA dossier has noticeably increased, but the nature of the existing guidelines and recommendations is rather fragmentary, which might create obstacles in the way of RWD/E study development and submission. The publication is aimed to describe and summarize the main and most rapidly developing spheres of RWD/E applications and analyze the possibilities of using RWD/E in various HTA areas in the world and in the Russian Federation considering the main trends in the further HTA development.Keywords
This publication has 36 references indexed in Scilit:
- The Randomized Registry TrialAnnals of Surgery, 2017
- Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA AgenciesValue in Health, 2017
- GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real worldResearch Synthesis Methods, 2016
- Patientenrelevante Endpunkte und Surrogate in der frühen Nutzenbewertung von Arzneimitteln: erste ErfahrungenZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2014
- Implementing routine outcome monitoring in clinical practice: Benefits, challenges, and solutionsPsychotherapy Research, 2013
- The Italian post-marketing registriesPharmaceutical Programming, 2012
- Guide de la Haute autorité de santé (HAS) : les études post-inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodesTherapies, 2012
- Feasibility and challenges of independent research on drugs: the Italian Medicines Agency (AIFA) experienceEuropean Journal of Clinical Investigation, 2009
- Handbook for good clinical research practice (GCP): guidance for implementationJournal of Epidemiology and Community Health, 2007
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005